Brian Marckx, CFA
Long/short equity

Medgenics Looking To Exploit Orphan Drug Market With Its Novel Biopump Protein Therapy Technology

Snapshot

Medgenics, Inc. (NYSEMKT:MDGN) was founded in January 2000 in Israel, and remains a development-stage company with research focused on bringing a novel therapeutic protein platform technology to market. Research and development is done primarily from a Misgav, Israel facility, while the principal office is located in Wayne, PA.

The company is led by a highly experienced management team and board of directors. This includes chairman of the Board, Sol Barer, the founder and former chairman of Celgene. In September 2013, the company brought on new executive management with highly impressive and relevant backgrounds, including a new CEO, CFO and global head of R&D, with a specific goal of accelerating development of the Biopump technology. Michael Cola, the

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details